CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...
Agios Pharmaceuticals is a biotech company focused on developing medicines for cancer and rare genetic diseases. The company's financials show growth, with increased product revenue and a reduction in ...
Agios’ Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 ...
Agios Pharmaceuticals, Inc. announced it will host a conference call and live webcast on July 31, 2025, at 8:00 a.m. ET to discuss its second quarter financial results and business updates. The ...
Agios Pharmaceuticals said it agreed with Celgene to end a three-year-old collaboration to develop and commercialize treatments containing its most advanced clinical cancer candidate AG-881 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results